Table 1

Clinicopathological features by hydronephrosis status

No hydronephrosisHydronephrosis
Group I (n=62)With reliefWithout relief
Group II (n=44)Group III (n=45)
Age*53.6±15.247.2±4.6†52.3±14.7
Race‡
 White34 (54.8)26 (59.1)25 (55.5)
 Black7 (11.3)4 (9.1)3 (6.7)
Pardo 20 (32.3)14 (31.8)17 (37.8)
 Other1 (1.6)00
Stage‡
 IIIB16 (25.8)11 (25)8 (17.8)
 IIIC133 (53.2)21 (47.7)23 (51.1)
 IIIC25 (8.1)3 (6.8)2 (4.4)
 IVA8 (12.9)9 (20.5)12 (26.7)
Histological type‡
 SCC57 (91.9)43 (97.7)43 (95.6)
 ADC3 (4.8)1 (2.3)2 (4.4)
 Other2 (3.2)00
Histological degree‡
 I3 (4.8)02 (4.4)
 II44 (71)30 (68.2)30 (66.7)
 III15 (24.2)14 (31.8)13 (28.9)
Tumor size (cm)§6.2 (5.75–7.3)6.2 (5–7.6)6.3 (5.5–8.1)
Parametrial involvement‡61 (98.4)43 (97.7)45 (100)
Pelvic lymphadenopathy‡42 (67.7)24 (54.5)26 (57.8)
Retroperitoneal lynphadenopathy‡6 (9.7)3 (6.8)2 (4.4)
Creatinine clearance at admission (mL/min)§97 (80.5–117)64 (34–98.5)¶77 (58–103)**
Treatment‡
 CCRT60 (96.8)38 (86.4)32 (71.1)**
 RT alone2 (3.2)6 (13.6)12 (26.7)**
 CT alone001 (2.2)
  • Data expressed as number (%); mean±SD; median (IQR)

  • *Analysis of variance with post hoc Tukey’s multiple comparisons test.

  • †Group I vs II - p<0.05.

  • ‡Fisher’s exact test or Χ2 test.

  • §Kruskal-Wallis test with post hoc Dunn’s multiple comparisons test.

  • ¶Group I vs II - p<0.001.

  • **Group I vs III - p<0.05.

  • ADC, adenocarcinoma; CCRT, concurrent chemoradiation therapy; CT, chemotherapy; RT, radiation therapy; SCC, squamous cell carcinoma.